Shanghai Pharmaceuticals Holding Co.,Ltd
Research Shanghai Pharmaceuticals Holding Co.,Ltd (601607.SS) on Bullrun: market cap CNY 61.60B, P/E 12.9, dividend yield 3.5%. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- Ticker601607.SS
- ExchangeSS
- CountryChina
- SectorHealthcare
- IndustryMedical Distribution
- CurrencyCNY
- Market capCNY 61.60B
- P/E12.9
- Dividend yield3.5%
- Financial periodQ2 2026
- RevenueCNY 72.21B
- Net incomeCNY 2.09B
- Free cash flowCNY 5.11B
- Gross margin11.3%
Valuation Snapshot
latest market cap is CNY 61.60B; P/E is 12.9; dividend yield is 3.5%.
Peer valuation comparison
Latest P/E is 12.88x versus a Healthcare sector median of 21.69x (40.6% below).
Latest dividend yield is 3.47% versus a Healthcare sector median of 2.41% (44.0% above).
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-10-18 | CNY 61.60B | 12.9 | 2.7% | 0.45 |
Dividend history
Latest trailing dividend snapshot: annual dividend/share 0.45 CNY, yield 3.5%.
About Shanghai Pharmaceuticals Holding Co.,Ltd
Shanghai Pharmaceuticals Holding Co., Ltd. engages in the research, development, manufacture, and sale of pharmaceutical and healthcare products in China and internationally. The company operates through four segments: Production, Distribution, Retail, and Others.
Related stock research
Other Healthcare stocks
Frequently asked questions
What is Shanghai Pharmaceuticals Holding Co.,Ltd's market cap?
Shanghai Pharmaceuticals Holding Co.,Ltd's market capitalization is CNY 61.60B.
What is Shanghai Pharmaceuticals Holding Co.,Ltd's P/E ratio?
Shanghai Pharmaceuticals Holding Co.,Ltd's price-to-earnings (P/E) ratio is 12.9.
Does Shanghai Pharmaceuticals Holding Co.,Ltd pay a dividend?
Shanghai Pharmaceuticals Holding Co.,Ltd has a dividend yield of 3.5%.
What does Shanghai Pharmaceuticals Holding Co.,Ltd do?
Shanghai Pharmaceuticals Holding Co., Ltd. engages in the research, development, manufacture, and sale of pharmaceutical and healthcare products in China and internationally. The company operates through four segments: Production, Distribution, Retail, and Others. It offers chemical and biological drugs, Chinese medicine, health care products, and medical devices to treat immunology, psychiatric and neurological, tumor, cardiovascular, digestive metabolism, psychoneurotic, neoplasm, respiratory system, and anti-infection diseases, as well as invests in equity.